RxDoctor Payments Data

Lauren McDonald, MD

Ophthalmology · Gainesville, FLNPI 1851527055

Payments from drug & device makers

$1,420in general payments, 2019–2025

Across 37 payments — averaging $38.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$401
  • AbbVie$272
  • Glaukos Corporation$139
  • Amgen$124
  • Kala Pharmaceuticals, Inc.$119
  • Spark Therapeutics, Inc.$95
  • plus $270 from 6 others

What the payments were for

  • Food & beverage$1,40299%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,420 in reported general payments places this provider in the 40th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$565,248
Medicare patients
1,950
Services billed
5,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine43$40,701
XiidraLifitegrast12$12,900
BesivanceBesifloxacin Hcl49$10,783
Cyclosporine16$10,213
Prednisolone Acetate199$10,152
RocklatanNetarsudil Mesylat/Latanoprost15$9,466
ProlensaBromfenac Sodium26$9,054
LumiganBimatoprost18$7,839
Latanoprost552$7,060
Travoprost40$5,877
Timolol Maleate215$5,490
VyzultaLatanoprostene Bunod13$5,093
CombiganBrimonidine Tartrate/Timolol11$3,879
SimbrinzaBrinzolamide/Brimonidine Tart15$3,766
Brimonidine Tartrate135$3,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$272$55,53686 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa$24$19,83775 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$84$17,99325 claims
AlconSimbrinza$401$3,76615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →